Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers from Sylvester Comprehensive Cancer Center are presenting their latest hematology research at the American Society of Hematology (ASH) Annual Meeting. Highlights include the discovery of a potent inhibitor of Lysine demethylase Lsd-1, which augments pro-differentiation effects in acute myeloid leukemia (AML), and targeting ...
Researchers at UC San Diego School of Medicine discovered a specific group of proteins decrease, triggering changes in the cancer microenvironment and accelerating growth of therapy-resistant CSCs. A targeted monoclonal antibody treatment effectively impaired CSC regeneration and made them easier to target with existing therapies.
A team of researchers discovered how a new anti-leukemia drug, JQ1, works by inhibiting BRD4 and causing the NSD3-short protein to 'fly apart', disrupting cancer cell growth. The NSD3-short protein acts as an adaptor protein, coupling BRD4 to CHD8, and has four distinct functions necessary for AML cells to thrive.
The study found that prices for all surveyed classes of brand-name drugs increased by an average of 401%, with topical antineoplastic drugs experiencing the largest percentage increase at 1240%. Psoriasis medications had the smallest average percentage increase, rising by just 180%.
Scientists have mapped out the human genome to identify essential genes for cell survival, revealing a core set of over 1,500 genes. The findings suggest that each tumor relies on a unique set of genes that can be targeted by specific drugs, offering hope for devising new treatments.
The latest Special Issue in ecancermedicalscience explores the intersection of biomarkers, screening and prevention using pharmaceutical agents. Researchers discuss validated biomarkers, chemoprevention and its challenges, as well as innovative approaches like circulating free-micro RNAs and circulating tumour DNA.
A preclinical study finds that AR-42, an HDAC inhibitor, preserves muscle health and function while stopping life-threatening muscle wasting associated with advanced cancers. The experimental agent was shown to have a strong protective effect against tumor-associated muscle wasting in two preclinical models.
Immune cells called Langerhans cells can uniquely repair DNA damage caused by radiotherapy, making them resistant to treatment. Researchers found that mimicking immunotherapy drugs can block this ability, preventing immune response and improving radiation therapy effectiveness.
A team of U of T engineers has developed a way to grow cancer cells in the form of a rolled-up sheet that mimics the 3D environment of a tumour, offering a way to speed up drug development and ask new questions about cell behavior. The single-layer design makes it easier for other lab researchers to adopt the process.
Researchers found p53 blocks PDL1 protein, which halts immune attack on lung cancer cells. High levels of p53 and miR-34a increase survival rates in patients with lung cancer.
Health experts argue that pharmaceutical companies abuse the Orphan Drug Act by marketing drugs for common conditions, generating billions in profits. The law was designed to encourage rare disease treatments but has instead led to high medication costs and monopolies.
A recent study by Georgetown University researchers reveals that wheelchair users are approximately 36% more likely to die in road traffic collisions. The majority of fatal crashes occurred at intersections with poor pedestrian infrastructure, indicating the need for improved accessibility and safety measures.
A new personalized method for testing drug effectiveness in multiple myeloma predicts the best treatments for individual patients. The test suggests commonly prescribed drugs or combination therapies, as well as optimal dosages.
Researchers at Brigham Young University create a system to speed up vaccine production by storing the biological machinery in a freeze-dried state. This allows labs to rapidly produce vaccines with just the addition of water, reducing the time from months to days.
A University of Colorado Cancer Center study shows that breast cancer patients without prescription drug coverage are less likely to start and continue hormonal therapy due to high costs. Women from lower-income households were particularly affected, highlighting the need for affordable prescription coverage.
A broad-spectrum approach to cancer treatment and prevention is being developed by researchers, focusing on low-toxicity agents from plants and foods that target multiple pathways involved in cancer development. The approach aims to improve upon current targeted therapies and reduce costs associated with toxicity and treatment duration.
A new study funded by The Ben & Catherine Ivy Foundation has identified propentofylline as a potential drug that could help treat glioblastoma multiforme (GBM), a deadly brain tumor. The research found that PPF can limit the spread of GBM and increase the effectiveness of chemotherapy drugs and radiation therapy.
A new study by Oregon State University reveals that rural residents aged 85 or older have higher levels of chronic disease, take more medications, and die earlier than their urban counterparts. The research highlights the challenges faced by older populations in rural areas due to limited access to healthcare services.
A study at MD Anderson Cancer Center found that suppressing epithelial-to-mesenchymal transition (EMT) in combination with gemcitabine may boost the drug's effectiveness against pancreatic cancer. EMT suppression leads to impaired sensitivity to chemotherapy, causing poor prognosis and metastasis.
A new blood test can detect when breast cancers become resistant to standard hormone treatment, allowing for early identification and alternative treatment options. Researchers developed the test to identify ESR1 mutations, which convey resistance to hormone treatment.
Researchers discover a link between colorectal cancer and melanoma treatment NT157, targeting both tumor cells and microenvironment to suppress cancer growth. The compound's dual mechanism of action shows promise in treating colon cancer with minimal damage to non-cancer cells.
A new study suggests that rare 'missense' mutations in the HER2 gene may not cause breast cancer growth or spread on their own. The research team found that such mutations may also fail to predict response to anti-cancer drugs targeting the HER2 gene, unlike common amplification alterations.
Researchers have discovered a new genetic cause of childhood kidney cancer, Wilms tumour, linked to mutations in the REST gene. The study found that REST mutations occur in about 10% of familial cases and can be detected through simple blood tests, providing valuable information for families affected by the disease.
Researchers at Temple University Health System have discovered a small molecule inhibitor that selectively kills cancer cells with BRCA1 or BRCA2 gene mutations. The compound, 6-hydroxy-DL-dopa, works by blocking an alternative DNA repair pathway, providing a promising approach to precision medicine for various cancers.
Experts discuss the impact of affordable medicines on breast cancer treatment, highlighting the importance of healthcare structures in improving patient outcomes. The lack of effective systems can negate even new, expensive treatments.
Researchers have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug. The test predicts which patients will not respond to treatment and can inform personalized treatment options.
Australian scientists identified a critical molecular feedback loop in neuroblastoma that accelerates cancer development. Experimental drug CBL0137 has the potential to interrupt this loop and halt tumour progression, showing promising results in laboratory models.
A BU School of Medicine researcher has identified a small molecule that selectively kills ALT-positive cancer cells, offering a potential therapeutic approach to deadly forms of human cancer. The discovery targets the ALT pathway, frequently reactivated in aggressive cancers such as osteosarcoma and glioblastoma.
A new study found that breast cancer adjuvant therapies have varying effects on patients over time. Researchers analyzed 19 clinical trials and discovered nearly half showed time-varying treatment effects.
A study published in JAMA Dermatology found that a common heart medication can stop the progression of angiosarcoma, a highly lethal blood vessel cancer. The treatment used propranolol, which costs significantly less than current therapies.
A recent study found that antiangiogenic breast cancer treatment primarily benefits patients with highly perfused tumors. The treatment reduced pressure within tumors and improved blood vessel density, but its effectiveness depends on the tumor's microvascular density before treatment.
Researchers at University of Oxford have discovered a new treatment targeting cancer cells with specific SETD2 mutations. The innovative approach uses a drug inhibiting WEE1 protein, exploiting synthetic lethality to selectively kill cancer cells.
New liposome technology allows for targeted delivery of cancer drugs, using heat-activated triggers to control release. This innovative approach could reduce collateral damage and improve treatment efficacy.
Dr. Emily Scott's work focuses on understanding how cytochrome P450s remove foreign chemicals from the body, allowing physicians to determine optimal medication frequencies and prevent diseases like cancer. Her lab is now working to stabilize interactions between P450s and helper proteins.
Researchers have discovered a genomic molecular fingerprint, signature 3, that highlights certain gastric cancers susceptible to treatment with platinum drugs or PARP inhibitor drugs. This biomarker could guide targeted therapy for breast, ovarian and pancreatic cancers as well.
The new approach uses a single chemical compound that makes cancer cells glow when exposed to near-infrared light, allowing for more effective removal of tumors. In laboratory tests, tumors were completely eradicated without side effects, and the treatment showed promise in targeting specific cancers.
A study published in JAMA Oncology found that superlatives like 'breakthrough' and 'miracle' were used to describe unapproved cancer drugs, often without clinical data. Targeted therapy was the most commonly referenced class of drugs, with immunologic checkpoint inhibitors also being frequently described as 'game-changers'.
Franziska Michor is awarded the NYSCF -- Robertson Stem Cell Prize for her interdisciplinary research on cancer genesis, using mathematical models to understand cancer evolution. Her work simulates drug treatment regimens and has been tested in clinical trials for non-small-cell lung cancer and brain tumors.
A new clinical trial has shown that a gene-targeted drug, olaparib, can benefit up to 33% of patients with treatment-resistant advanced prostate cancer. The trial found that men whose tumours had defects in DNA repair machinery responded particularly well to the drug.
A retrospective survival analysis of 229 patients with late-stage cancer found that those who received methylnaltrexone lived twice as long and had fewer tumor progression reports compared to placebo groups. The study suggests methylnaltrexone may play a role in cancer therapy, but the exact mechanism is unclear.
Researchers discovered a protein called Zmiz1 that sticks to the Notch gene, triggering its cancer function. Deleting Zmiz1 from Notch eliminates the cancer effect while preserving normal health functions.
PharmaMar presents new studies on the treatment of ovarian cancer using YONDELIS (trabectedin) and PM1183, showing promising results in managing recurrent cancer. The studies highlight the potential benefits of combining these therapies to improve patient outcomes.
Researchers have discovered molecular changes within tumors that prevent immunotherapy drugs from killing off cancer cells. By reprogramming an epigenetic mechanism, the therapy might work for more patients, according to senior author Weiping Zou.
Researchers have discovered a new combination of drugs that may be effective against resistant, BRAF-mutant melanoma by targeting different signaling pathways. The combination showed synergistic effects in tumors resistant to BRAF inhibition.
Scientists have created a highly specific chemical probe that switches off two important proteins implicated in cancer cell proliferation. The probe, CCT251545, selectively binds to CDK8 and CDK19, blocking the WNT signalling pathway and providing new insights into their role in driving cancer growth.
This special issue examines cancer screening, treatment, survivorship, access to care, and global health. Research articles investigate colorectal cancer screening, patient perceptions of stool DNA-based testing, financial barriers to specialty care for uninsured patients, and the role of primary health care in China's reform.
Scientists at Sanford Burnham Prebys Medical Discovery Institute used publicly available cancer databases to identify novel cancer driver genes associated with cancer progression. The study found 71 previously unrecognized interfaces in proteins that may serve as new predictive markers or drug targets.
Biosimilars are complex proteins that provide therapeutically equivalent alternatives to expensive biologics, reducing treatment costs in rheumatology and other fields. The introduction of biosimilars into clinical practice requires careful management to ensure patient safety and efficacy.
A small phase I clinical trial found that an FDA-approved leukemia drug improved cognition, motor skills, and non-motor function in patients with Parkinson's disease and Lewy body dementia. The drug, nilotinib, also reduced toxic proteins linked to disease progression.
A study published in Science reveals a mechanism that allows key immune system cells to restrain their more aggressive brother cells, protecting healthy tissue from assault. By targeting this genetic pathway with drugs, it may be possible to convert these cells into cancer-fighting cells.
Researchers have discovered a protein in malaria that can bind to a sugar molecule found in many types of cancer. This binding enables anti-cancer drugs to be delivered precisely to tumors. The findings offer new potential for treating various cancers, including melanoma and lung cancer.
Scientists have developed a blood test that can pair cancer patients with the most suitable therapy for their disease, giving real-time updates on tumor progression. This approach could make diagnosis, treatment, and monitoring quicker, cheaper, and less invasive.
Researchers have identified distinct microbial signatures in triple negative breast cancer tissue, suggesting potential diagnostic and therapeutic applications. The study found a predominantly viral and bacterial signature, with some fungi and parasites also present.
Case Western Reserve University researcher Efstathios Karathanasis has received a $2.82 million grant to develop a treatment that eradicates glioblastoma multiforme with one safe dose. The treatment uses chain-like nanoparticles carrying chemotherapy medicine and inhibitors to target brain tumor cells.
A University of Colorado Cancer Center study found TAK-733 to be highly active against colorectal cancer cells and tumors, with 42 of 54 cell lines sensitive to the drug. However, inconsistent absorption and bioavailability were observed, raising concerns about safety and tolerability.
Scientists discovered a malaria protein that targets sugar molecules found in placentas and most cancers, leading to the development of an anti-cancer drug. The new approach halted tumour growth in mice and showed promising results in treating non-Hodgkin's lymphoma, prostate cancer, and metastatic breast cancer.
Researchers discovered a malaria protein that binds to a common sugar molecule found on both placentas and cancer cells. A novel technology was developed to arm antibodies with high potency toxins to specifically kill cancer cells, showing promising results in clinical trials.
Childhood cancer survivors showed significant improvements in working memory, attention, and processing speed after completing computer-based cognitive training. The training program, using Cogmed, improved performance comparable to stimulant medications and showed changes in brain activity suggesting neuroplasticity.
Researchers identified four consensus molecular subtypes of bowel cancer, allowing doctors to treat each type differently. The study has implications for identifying patients at risk of developing more serious disease and tailoring treatments.
A comprehensive study of non-protein-coding RNAs in human cancers has identified alterations linked to 13 different cancer types. The research provides a rich resource for investigating lncRNA dysregulation and identifying potential diagnostic and therapeutic tools.